Author Archive: Abigail Hirsch

Abigail Hirsch

Abigail is the Director of Events Communications at BIO. Although she has lived in the Washington, DC, area for nearly eight years, she still considers Virginia Beach home, especially with her parents and closest friends still in the area. According to Abigail, there is nothing better than sitting on the beach with a good book and cold drink. In her spare time, she enjoys visiting antique stores, finishing her twin sister Brooke’s sentences and spending time with her two boys, Frank her English bulldog, and JP her soon-to-be husband. Check back often for updates, Abigail’s take on BIO related events, and much more. And please, be kind, this is her first venture in to the blogging world!

Latest Posts

2015 BIO CEO & Investor Conference™ Buzz of BIO Nominations Open

CEO-BuzzofBIO

For the first time, the Buzz of BIO contest will take place at the 2015 BIO CEO & Investor Conference.  Sponsored by BioCentury and Tiberend Strategic Advisors, the contest recognizes highly innovative companies in the biotech sector and helps position these companies to develop strategic partnerships within the industry. Ten biotechs will be nominated in each of two categories – Most Distinguished Public Company and Most Promising Private Company. Buzz of BIO nominations are now Read More >

Events  |  Leave a comment  |  Email This Post

2015 BIO CEO & Investor Conference™ to Feature Dynamic List of Company Presentations

CEO-BuzzofBIO

Past and future attendees of the annual BIO CEO & Investor Conference have high expectations for the caliber of company’s chosen to present at the event. Presenting companies are hand selected for the event and consist of a selection of mid to large cap established public companies from around the globe who typically have a clinical stage program centered on therapeutics, molecular diagnostics, or a platform technology, as well as an upcoming clinical, regulatory or Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Blurred Lines: Investors Explain Their Re-Thinking of Traditional Private-Only or Public-Only Investment Strategies

DSC_8551

The recent expansion and acceleration of the biotech stock market has seen a new willingness and in some cases eagerness to pursue crossover investing in firms pre- and post-IPO. Venture capitalists have become less dogmatic about funding stage and equity share when positive returns seem nearly guaranteed and investment banks are engaging in discussions with entrepreneurs earlier than ever. Relatedly, corporate venture capital executives’ missions have broadened to consider more diverse forms of collaboration than Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Tekmira Pharmaceuticals Ebola Drug Gets Nod From FDA

BIO Investor Forum

The U.S. Food and Drug Administration has authorized Canada’s Tekmira Pharmaceuticals to provide an experimental drug to people with confirmed or suspected Ebola virus infections, according to an article in The Wall Street Journal. “Our TKM-Ebola drug supplies are limited, but we will continue to help where we can,” Tekmira Chief Executive Mark J. Murray said in a press release. The drug is still in clinical testing to assess whether it is safe and effective. BIO Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

The Eyes Have It According to Recent VC Funding Patterns

BIO Investor Forum

A recent Wall Street Journal analysis of venture capital investment trends since 1999 reveals which human body parts are experiencing the biggest rise in funding. The report was based on data from thousands of financings of startups from 1999 through the first half of 2014, provided by VentureSource, a database owned by Dow Jones & Company. And while many would assume the funding was largely pumped in to cardiovascular disease, they would be wrong. “The Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,